The risk test for recurrence and extended endocrine breast cancer index (BCI) testing is intended for patients with positive estrogen receptor diagnosis (ER +), lymph node negative (LN-) positive lymph node ( LN +, positive lymph nodes) early stage, invasive breast cancer, which are distant without recurrence. BCI provides: 1) a quantitative assessment of the probability of both late (post-5 years) and global (0-10 years) recurrence after 5 years of initial endocrine therapy (LN patient) or 5 years of endocrine therapy plus adjuvant chemotherapy (patient LN +), and 2) predicting the likelihood of prolonged endocrine therapy (> 5 years). The BCI results are added to the doctor’s record; treatment decisions require correlation with all other clinical findings.
